Cellivery Reports 'COVID-19' Immune Therapy iCP-NI at American Association for Cancer Research

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 21st that it reported 'Innate Immunity Control Antiviral and Anti-inflammatory Novel Coronavirus Disease (COVID-19) Immunotherapeutic iCP-NI' at the 'COVID-19 & CANCER' special conference hosted by the American Association for Cancer Research (AACR).

At this COVID-19 and Cancer conference, Dr. Anthony Fauci, Director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), participated as the keynote speaker. The latest research results on treatments and vaccines related to the ongoing global COVID-19 pandemic were presented.

Cellivery's presentation was titled "Intracellular delivery of nuclear localization signal sequences regulates cytokine and chemokine expression to suppress inflammatory responses caused by COVID-19."

Cellivery focused its presentation on outstanding antiviral and anti-inflammatory results derived from viral infection rodent models (mice) and COVID-19 infected primate models (monkeys). iCP-NI controls innate immunity to inhibit immune cell destruction caused by cytokine storms. It was introduced as a COVID-19 immunotherapeutic that exhibits antiviral and anti-inflammatory effects by enabling activated innate immune cells to simultaneously eliminate viruses and virus-infected pulmonary bronchial cells.

According to Cellivery, after a single administration of iCP-NI, clinical signs in COVID-19 infected monkeys such as oxygen saturation, respiratory rate per minute, heart rate, and blood glucose levels returned to normal levels, and the amount of coronavirus in the respiratory tract decreased. The company explained that very excellent therapeutic efficacy was reported.

Daewoong Cho, CEO of Cellivery, said, "Through participation in the special conference, we reported the existence and efficacy evaluation results of iCP-NI to academia and industry for the first time, and by publicly announcing the development status of iCP-NI as a COVID-19 therapeutic worldwide, we have received great interest from global pharmaceutical companies participating in the event. We will do our best to industrialize iCP-NI as a COVID-19 immunotherapeutic in the shortest possible time by actively utilizing it for licensing-out (L/O) business simultaneously with independent clinical development."

This content was produced with the assistance of AI translation services.